Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGb-0301
- Development stage
- Phase 1
- Lead developer
- Sichuan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular
01
Overview
WGb-0301 is an experimental mRNA-based immunotherapy developed by Sichuan University for the treatment of relapsed and refractory B-cell malignancies, including B-cell lymphoma and lymphocytic leukemia. The therapeutic consists of messenger RNA (mRNA) encoding a specific protein targeting the CD19 antigen, encapsulated within lipid nanoparticles (LNPs). Upon administration via injection, the mRNA is delivered to cells to express the target protein, which then mediates the clearance of CD19-positive B-cells. WGb-0301 is designed to provide an innovative and accessible alternative to traditional cell therapies, demonstrating efficient B-cell clearance and a favorable safety profile in non-clinical studies. It is currently undergoing exploratory clinical evaluation in patients with B-cell malignant tumors.
- Other names
- WGb-0301 injectionWGb0301 injectionWGb 0301 injection
02
Targets
Beyond the preview
Go deeper on WGb-0301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGb-0301.